Similarly, RRM2 inhibition could sensitize cells to temozolomide chemotherapy.25,26 Lastly, colleagues have recently demonstrated that the MAPK-targeting agent MEK162 was found to enhance the effect of radiotherapy on GBM cells in their in vitro and in vivo GBM model.18 Based on the results of these studies, the efficacy of the antineoplastic drugs targeting RRM2, XIAP, and MAPK9 combined with temozolomide and/or radiotherapy still warrants further investigation. This evidence concerns the gene MAPK9 and glioblastoma.